Bifogade filer
PDF
Kurs & Likviditet
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Mid Cap Stockholm |
| Sektor | Hälsovård |
| Industri | Läkemedel & Handel |
Kalender
| 2022-10-21 | Kvartalsrapport 2022-Q3 |
| 2022-07-22 | Kvartalsrapport 2022-Q2 |
| 2022-05-06 | Årsstämma 2022 |
| 2022-05-06 | Kvartalsrapport 2022-Q1 |
| 2022-02-04 | Bokslutskommuniké 2021 |
| 2021-10-21 | Kvartalsrapport 2021-Q3 |
| 2021-08-12 | Kvartalsrapport 2021-Q2 |
| 2021-05-07 | Ordinarie utdelning BIOG B 3.41 SEK |
| 2021-05-06 | Kvartalsrapport 2021-Q1 |
| 2021-05-06 | Årsstämma 2021 |
| 2021-02-04 | Bokslutskommuniké 2020 |
| 2020-11-25 | Extra Bolagsstämma 2020 |
| 2020-10-23 | Kvartalsrapport 2020-Q3 |
| 2020-08-13 | Kvartalsrapport 2020-Q2 |
| 2020-05-08 | Ordinarie utdelning BIOG B 3.75 SEK |
| 2020-05-07 | Årsstämma 2020 |
| 2020-05-07 | Kvartalsrapport 2020-Q1 |
| 2020-02-06 | Bokslutskommuniké 2019 |
| 2019-10-23 | Kvartalsrapport 2019-Q3 |
| 2019-05-09 | Ordinarie utdelning BIOG B 4.05 SEK |
| 2019-05-09 | Bonusutdelning BIOG B 5.95 |
| 2019-02-07 | Bokslutskommuniké 2018 |
| 2018-10-24 | Kvartalsrapport 2018-Q3 |
| 2018-08-17 | Kvartalsrapport 2018-Q2 |
| 2018-04-26 | Ordinarie utdelning BIOG B 4.31 SEK |
| 2018-04-26 | Bonusutdelning BIOG B 4.69 |
| 2018-04-25 | Årsstämma 2018 |
| 2018-04-25 | Kvartalsrapport 2018-Q1 |
| 2018-02-08 | Bokslutskommuniké 2017 |
| 2017-10-25 | Kvartalsrapport 2017-Q3 |
| 2017-08-18 | Kvartalsrapport 2017-Q2 |
| 2017-05-04 | Ordinarie utdelning BIOG B 3.16 SEK |
| 2017-05-04 | Bonusutdelning BIOG B 4.34 |
| 2017-05-03 | Kvartalsrapport 2017-Q1 |
| 2017-05-03 | Årsstämma 2017 |
| 2017-02-10 | Bokslutskommuniké 2016 |
| 2016-10-25 | Kvartalsrapport 2016-Q3 |
| 2016-08-17 | Kvartalsrapport 2016-Q2 |
| 2016-05-11 | Ordinarie utdelning BIOG B 3.03 SEK |
| 2016-05-11 | Bonusutdelning BIOG B 1.97 |
| 2016-05-10 | Kvartalsrapport 2016-Q1 |
| 2016-05-10 | Årsstämma 2016 |
| 2016-03-18 | Extra Bolagsstämma 2016 |
| 2016-02-12 | Bokslutskommuniké 2015 |
| 2015-10-23 | Kvartalsrapport 2015-Q3 |
| 2015-08-18 | Kvartalsrapport 2015-Q2 |
| 2015-05-08 | Ordinarie utdelning BIOG B 3.46 SEK |
| 2015-05-08 | Bonusutdelning BIOG B 1.54 |
| 2015-05-07 | Årsstämma 2015 |
| 2015-05-07 | Kvartalsrapport 2015-Q1 |
| 2015-02-12 | Bokslutskommuniké 2014 |
| 2014-10-22 | Kvartalsrapport 2014-Q3 |
| 2014-08-20 | Kvartalsrapport 2014-Q2 |
| 2014-05-07 | Bonusutdelning BIOG B 3.65 |
| 2014-05-07 | Ordinarie utdelning BIOG B 3.35 SEK |
| 2014-05-06 | Årsstämma 2014 |
| 2014-05-06 | Kvartalsrapport 2014-Q1 |
| 2014-02-12 | Bokslutskommuniké 2013 |
| 2013-10-23 | Kvartalsrapport 2013-Q3 |
| 2013-08-22 | Kvartalsrapport 2013-Q2 |
| 2013-04-29 | Ordinarie utdelning BIOG B 4.15 SEK |
| 2013-04-29 | Bonusutdelning BIOG B 5.85 |
| 2013-04-26 | Årsstämma 2013 |
| 2013-04-26 | Analytiker möte 2013 |
| 2013-04-26 | Kvartalsrapport 2013-Q1 |
| 2013-02-08 | Bokslutskommuniké 2012 |
| 2012-10-23 | Kvartalsrapport 2012-Q3 |
| 2012-10-23 | Analytiker möte 2012 |
| 2012-08-21 | Kvartalsrapport 2012-Q2 |
| 2012-05-09 | Bonusutdelning BIOG B 2.74 |
| 2012-05-09 | Ordinarie utdelning BIOG B 1.26 SEK |
| 2012-05-08 | Årsstämma 2012 |
| 2012-05-08 | Kvartalsrapport 2012-Q1 |
| 2012-02-10 | Bokslutskommuniké 2011 |
| 2011-11-17 | Kapitalmarknadsdag 2011 |
| 2011-10-25 | Kvartalsrapport 2011-Q3 |
| 2011-05-11 | Bonusutdelning BIOG B 1.08 |
| 2011-05-11 | Ordinarie utdelning BIOG B 0.92 SEK |
| 2011-05-10 | Årsstämma 2011 |
| 2011-05-10 | Kvartalsrapport 2011-Q1 |
| 2011-02-11 | Bokslutskommuniké 2010 |
| 2010-10-27 | Kvartalsrapport 2010-Q3 |
| 2010-08-17 | Kvartalsrapport 2010-Q2 |
| 2010-05-07 | Bonusutdelning BIOG B 0.6 |
| 2010-05-07 | Ordinarie utdelning BIOG B 0.90 SEK |
| 2010-05-06 | Kvartalsrapport 2010-Q1 |
| 2010-02-22 | Bokslutskommuniké 2009 |
| 2009-10-22 | Kvartalsrapport 2009-Q3 |
| 2009-08-18 | Kvartalsrapport 2009-Q2 |
| 2009-04-23 | Ordinarie utdelning BIOG B 0.40 SEK |
| 2009-04-22 | Årsstämma 1 |
| 2009-04-22 | Kvartalsrapport 2009-Q1 |
MetaboGen aims at developing next generation probiotic products focusing on metabolic conditions with special emphasis on diabetes and related diseases. The company has now received approval from the Ethics Committee to start a new clinical study.
After obtaining positive results in the initial clinical study with the strains Faecalibacterium prausnitzii (DSM 32379) and Desulfovibrio piger (DSM 32187), MetaboGen has now received approval from the Ethics Committee to proceed into its next clinical study, targeting a pre-diabetic population.
"We are really looking forward to the outcome of our next clinical study. In parallel we are working on the optimization of our production processes to prepare for commercial scale. The bacteria we work with are very sensitive to oxygen, so we have developed and patented a unique production technology which helps us overcome this challenge. We are very excited about these next steps and look forward to launching our first product," says Sara Malcus, Managing Director of MetaboGen.
Latest press releases from BioGaia
04.02.2021 BioGaia AB - Year-end report 2020
03.02.2021 BioGaia revises dividend policy
27.01.2021 BioGaia invests in Sweden - launches its entire adult health portfolio
Sara Malcus, Managing Director of MetaboGen: +46 705 82 32 22
Isabelle Ducellier, CEO of BioGaia: +46 8 555 293 00